Today, our clinical efforts are primarily focused on Orphan diseases such as hereditary angioedema and in transplant medicine. Our goal is to bring new therapeutic alternatives to patients with potentially life threatening diseases that carry the risks of significant morbidity/mortality and a low quality of life. And, if successful, our work will provide such drugs to patients whose needs are not being met by their current therapeutic options.

ViroPharma's FDA-approved product CINRYZE^® (C1 Esterase Inhibitor [human]) is indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE). ViroPharma is the industry leader in physician education about HAE, with the goal of assisting physicians in rapid identification of the disease and improving communication about current therapeutic alternatives for these patients.

ViroPharma commercializes VANCOCIN® (Vancomycin Hydrochloride Capsules, USP), a life saving drug for patients suffering from severe Clostridium difficile infection (CDI). Our mission, as stewards of public health related to CDI, is to do all that we can - in every way that we can - by working with physicians toward enabling quick identification and appropriate treatment of patients who are most at risk of severe disease, and to keep other patients infection-free.

Learn more about our therapeutic areas, including Orphan Diseases and hospital/transplant medicine.

Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE) is an autosomal dominant disease characterized by painful, unpredictable, recurrent attacks of inflammation affecting the hands, feet, face, abdomen, urogenital tract, and the larynx. Learn More

Clostridium difficile-Infection (CDI)

C. difficile infection has become one of the most common nosocomial (spread patient to patient in a hospital) infections. Learn More